10429-07-9

Basic information

• Product Name: 3β-tosyloxy-5α-androstan-17-one
• Synonyms: 3β-tosyloxy-5α-androstan-17-one
• CAS NO: 10429-07-9
• Molecular Weight: 444.635
• Mol File: 10429-07-9.mol
• Article Data: 13

Chemical Properties

• Density: 1.18g/cm3 at 25℃
• CAS DataBase Reference: 3β-tosyloxy-5α-androstan-17-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3β-tosyloxy-5α-androstan-17-one(10429-07-9)
• EPA Substance Registry System: 3β-tosyloxy-5α-androstan-17-one(10429-07-9)

Safety Data

• Hazardous Substances Data: 10429-07-9(Hazardous Substances Data)

Usage

Uses

3β-(4-Methylphenylsulfonyloxy)-5α-androstan-17-one is an important reagent in the synthesis of aminosteroids and rocuronium bromide intermediate. Rocuronium bromide is an amino steroid non-depolarizing neuro muscular blocker. Also functions as a reagent in the preparation of androstanes as antiarrhythmics.

Upstream product

• 53-43-0 dehydroepiandrosterone 
• 481-29-8 Epiandrosterone 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 1164-95-0 androsterone acetate 
• 53-41-8 cis-androsterone 
• 14639-79-3 5α-androst-2-en-17-one 
• 4589-82-6 3α-Formoxy-5α-androstan-17-on 
• 104533-64-4 toluene-4-sulfonic acid ; S-(17-oxo-5α-androstan-3α-yl)-thiuronium-salt 
• 32625-08-4 17β-Hydroxy-3β-toluol-p-sulfonyloxy-5α-androstan 
• 846-46-8 androstanedione 
• 1156-86-1 3α-fluoro-5αH-androstan-17-one 
• 58507-05-4 (3S,5S,8R,9S,10S,13S,14S)-3-bromo-10,13-dimethylhexadecahydro-17H-cyclopenta[a]phenanthren-17-one 
• 53512-66-6 (3R,5S,8R,9S,10S,13S,14S)-3-bromo-10,13-dimethyltetradecahydro-1H-cyclopenta[a]phenanthren-17(2H)-one 
• 148773-59-5 3α-(phenylthio)androstan-17-one 
• 134511-57-2 p-toluenosulfonate of 3α-azido-5α-androstan-17β-ol 
• 1225-43-0 (5R,8R,9S,10S,13S,14S,17S)-10,13-Dimethyl-hexadecahydro-cyclopenta[a]phenanthren-17-ol 
• 963-74-6 5alpha-androstan-17-one 

Relevant articles and documents

Conversion of epiandrosterone into 17β-amino-5α-androstane

A new method for synthesizing 17β-amino-5α-androstane was developed based on tigogenin. The configuration at C-17 was proved by PMR.

METHODS OF ACTIVATING MICROGLIAL CELLS

The present disclosure provides methods of using compositions that inhibit SH2-containing inositol 5'-phosphatases (SHIPs) for activating microglial cells, as well as methods for using such compositions for treatment or ameliorating of neurodegenerative disorders in a subject.

NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF

Described herein are neuroactive steroids of the Formula (I): (Formula (I)) or a pharmaceutically acceptable salt thereof; wherein R1a and R1b are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.